What's Happening?
Medicare is set to begin covering obesity drugs through a new Bridge demonstration program starting July 1, 2026. This initiative will allow eligible beneficiaries to access GLP-1 drugs for obesity at a copay of $50 per month. The program aims to expand
access to medications previously unavailable to many seniors, potentially benefiting millions of older Americans. The Bridge program circumvents a federal law that previously prohibited coverage solely for obesity, allowing coverage for those with conditions like prediabetes or uncontrolled hypertension. However, insurers such as CVS and UnitedHealthcare have opted out of participating voluntarily, citing concerns about the program's structure and costs.
Why It's Important?
The introduction of Medicare coverage for obesity drugs marks a significant shift in healthcare policy, potentially unlocking a vast new patient population for pharmaceutical companies like Novo Nordisk and Eli Lilly. This move could lead to increased demand for obesity medications, impacting physicians, pharmacies, and the prior authorization process. The program's success could influence future healthcare policies and encourage private insurers to cover these drugs, potentially reducing healthcare costs by preventing related conditions like diabetes. However, the temporary nature of the program raises questions about long-term access and affordability for patients.
What's Next?
The Bridge program is set to run through 2027, with the Centers for Medicare & Medicaid Services (CMS) planning to use data from the demonstration to encourage participation in a longer-term program called Balance. The outcome of this initiative could pressure private insurers to include obesity drugs in their Part D plans. The healthcare system may face challenges in managing the anticipated surge in demand, requiring adjustments in clinic and pharmacy operations. The program's future beyond 2027 remains uncertain, dependent on policy changes or agreements among private insurers.
